Flavopiridol inversely affects p21WAF1/CIP1 and p53 and protects p21-sensitive cells from paclitaxel

被引:28
作者
Blagosklonny, MV
Darzynkiewicz, Z
Figg, WD
机构
[1] New York Med Coll, Branch Canc Res Inst, Hawthorne, NY 10532 USA
[2] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
flavopiridol; paclitaxel; p53; p21;
D O I
10.4161/cbt.1.4.21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resting cells are relatively resistant to microtubule-active drugs including paclitaxel (PTX). By causing p53-mediated arrest, pretreatment with low concentrations of doxorubicin (DOX) protected HCT116 cells from the cytotoxicity caused by PTX. Unlike DOX, flavopiridol (FL) did not protect HCT116 cells. Low concentrations of FL (50 nM) induced p21 but not p53. High concentrations of FL (500 nM) decreased levels of p21 and Mdm-2 but dramatically induced p53. Thus, FL reciprocally affects p21 and p53. In LNCaP, a prostate cancer cell line which is highly sensitive to p21-induced growth arrest (p21-sensitive), low concentrations of FL (50 nM) induced p21 (without induction of p53) and caused G1 and G2 arrest. This precluded mitotic arrest, Bcl-2 and Raf-1 phosphorylation, and diminished cell death caused by PTX. In contrast, FL did not protect PC3M, arrest-resitant and highly aggressive prostate cancer cells. Like LNCaP, HL60 and SKBr3 cells are known to be p21-sensitive. As predicted, low concentrations of FL antagonized PTX-mediated cytotoxicity in HL60 and SKBr3 cell lines. In summary, only low concentrations of FL can induce p21, and, in turn, only p21-sensitive cells are protected from PTX.
引用
收藏
页码:420 / 425
页数:6
相关论文
共 50 条
  • [21] p21WAF1/Cip1 - PCNA: Fatal attraction
    Galanos, Panagiotis
    Pappas, George
    Gorgoulis, Vassilis G.
    CELL CYCLE, 2016, 15 (23) : 3153 - 3154
  • [22] Expression and alteration of p53 and p21waf1/cip1 influence the sensitivity of chemoradiation therapy for esophageal cancer
    Shimoyama, S
    Konishi, T
    Kawahara, M
    Aoki, F
    Harada, N
    Shimizu, S
    Murakami, T
    Kaminishi, M
    HEPATO-GASTROENTEROLOGY, 1998, 45 (23) : 1497 - 1504
  • [23] Molecular-targeted approach to cancer therapy -: The roles of P53 and P21WAF1/CIP1 genes
    Kralj, Marijeta
    CURRENT STUDIES OF BIOTECHNOLOGY, VOL IV: IMMUNO-MODULATORY DRUGS, 2005, : 27 - 36
  • [24] Reduced p21WAF1/CIP1 protein expression is predominantly related to altered p53 in hepatocellular carcinomas
    Shi, YZ
    Hui, AM
    Takayama, T
    Li, X
    Cui, X
    Makuuchi, M
    BRITISH JOURNAL OF CANCER, 2000, 83 (01) : 50 - 55
  • [25] p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations
    Viale, G
    Pellegrini, C
    Mazzarol, G
    Maisonneuve, P
    Silverman, ML
    Bosari, S
    JOURNAL OF PATHOLOGY, 1999, 187 (03) : 302 - 307
  • [26] p21WAF1/CIP1 promotes p53 protein degradation by facilitating p53-Wip1 and p53-Mdm2 interaction
    Lee, Jihyun
    Kim, Jongdoo
    Kim, Eun Mi
    Kim, Ukjin
    Kang, A-Ram
    Park, Jong Kuk
    Um, Hong-Duck
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 543 : 23 - 28
  • [27] Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma
    De la Cueva, E.
    Garcia-Cao, I.
    Herranz, M.
    Lopez, P.
    Garcia-Palencia, P.
    Flores, J. M.
    Serrano, M.
    Fernandez-Piqueras, J.
    Martin-Caballero, J.
    ONCOGENE, 2006, 25 (29) : 4128 - 4132
  • [28] Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma
    E De la Cueva
    I García-Cao
    M Herranz
    P López
    P García-Palencia
    J M Flores
    M Serrano
    J Fernández-Piqueras
    J Martín-Caballero
    Oncogene, 2006, 25 : 4128 - 4132
  • [29] A novel p21WAF1/CIP1 transcript is highly dependent on p53 for its basal expression in mouse tissues
    Andrei L Gartel
    Senthil K Radhakrishnan
    Michael S Serfas
    Young H Kwon
    Angela L Tyner
    Oncogene, 2004, 23 : 8154 - 8157
  • [30] A novel p21WAF1/CIP1 transcript is highly dependent on p53 for its basal expression in mouse tissues
    Gartel, AL
    Radhakrishnan, SK
    Serfas, MS
    Kwon, YH
    Tyner, AL
    ONCOGENE, 2004, 23 (49) : 8154 - 8157